Substituted cycloalkyl P1' hepatitis C virus inhibitors
申请人:——
公开号:US20040077551A1
公开(公告)日:2004-04-22
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
Hepatitis C virus inhibitors having the general formula (I)
are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
[EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HEPATITE C
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2005051410A1
公开(公告)日:2005-06-09
Hepatitis C virus inhibitors are disclosed having the general formula (I) wherein A, R2, R3, R', B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.